Trump Tariff Impact on Gene Therapy

Hidden Costs. Strategic Risks. It’s Time for a Tariff Strategy.

The new Trump reciprocal tariffs — potentially as high as 54% on imports — are triggering a global supply chain reset. The gene therapy industry, heavily reliant on high-value biologics, vectors, and specialized manufacturing inputs, is starting to feel the heat. From soaring costs and regulatory delays to supply chain disruptions and investor uncertainty, gene therapy players are navigating uncharted territory.

Download our “Gene Therapy Tariff Threat Assessment” overview — a rapid, insight-driven engagement to help you act decisively.

US Tariff Impact on Gene Therapy Supply Chains and Cost Structures

• Dependence on imported viral vectors, cell lines, and reagents from Europe and Asia
• Tariffs inflating the cost of raw materials and contract manufacturing
• Cold chain logistics facing higher freight costs and customs delays
• Companies evaluating U.S.-based bioproduction and backup sourcing
• Pressure on long-term CDMO contracts and tech transfer agreements

Trump Tariff Impact on Gene Therapy Innovation and R&D

• Tariff-driven cost surges threatening early-stage research budgets
• Clinical trial delays due to procurement bottlenecks and customs hold-ups
• Smaller gene therapy startups most vulnerable to cash flow shocks
• Pipeline adjustments favoring near-commercial or U.S.-manufactured therapies
• Extended timelines for IND filings and regulatory readiness

US Tariff Impact Accelerating Domestic Biomanufacturing Strategies

• Increased focus on domestic vector production and gene editing platforms
• Capex-intensive facilities slow to scale due to labor and regulatory gaps
• Need for skilled cell/gene therapy technicians outpacing supply
• Incentives and partnerships being explored to stimulate U.S. production
• Heightened FDA oversight on new facility validations and compliance

Trump Tariff Impact on Regulatory and Compliance Operations

• Source changes and tech transfers triggering new FDA and EMA filings
• Requalification of materials delaying timelines for pivotal trials
• Greater exposure to global regulatory misalignment and audit risk
• Compliance teams burdened by additional documentation and QA processes
• Emerging need for digital QMS and regulatory harmonization tools

Sectors and Companies Likely to Be Affected by US Tariff Impact

Gene Therapy Developers
Companies like Bluebird Bio, Sarepta, Orchard Therapeutics, and Rocket Pharma face margin pressures and supply constraints.

CDMOs Specializing in Viral Vectors
Firms like Thermo Fisher, WuXi Advanced Therapies, and Catalent Cell & Gene may see rising demand but also supply chain hurdles.

Large Pharma Investing in Gene Therapy
Pfizer, Novartis, Roche, and Bayer must reassess global production hubs and import dependencies for their gene therapy pipelines.

Emerging Biotech and Academic Spinouts
Startups and university spinouts often lack the infrastructure to weather tariff shocks, making them highly vulnerable.

Clinical Trial Supply Chains
Service providers supporting Phase I-III gene therapy trials may experience cross-border logistics and customs-related delays.

What You Can Do Now

That’s why we’ve developed a fast, targeted offering to help gene therapy players like you quickly assess:
• Where you’re vulnerable – across vectors, inputs, CDMOs, and transit points
• How it impacts you financially – from margin compression to investor pushback
• What to do next – including sourcing strategy, facility reshoring, and customs planning

Conclusion: Navigating Trump Tariff Impact on Gene Therapy

Trump-era tariffs are reshaping the global trade landscape, and gene therapy — with its complex supply chains and sensitive materials — is particularly exposed. Companies that act now with smart, forward-looking tariff strategies will protect critical timelines, sustain R&D momentum, and stay ahead in an increasingly volatile market.

Get your Gene Therapy Trump Tariff Readiness Assessment

Related Reports:

Gene Therapy Market by Type (Gene silencing), Vector (Viral (Retroviral, AAV), Non-viral (Oligonucleotide)), Gene Type (Receptors, Cytokine), Therapeutic Area (Oncology, Neurology), Delivery Method (In-Vivo, Ex-Vivo), RoA (IV) - Global Forecast to 2032

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com